UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

[ ] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

[X] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period form August 1, 2002 to September 30, 2002

Commission file number 000-26309

NATUROL HOLDINGS LTD.
(Formerly Coronado Explorations Ltd.)
(Exact name of registrant as specified in its charter)

Delaware	**98-0200471**
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

6265 Stevenson Way	
Las Vegas, Nevada, USA	**89120**
(Address of principal executive offices)	(zip code)

Issuer's Telephone Number: **(702) 450-1600**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes __X__ No ____

The number of shares of Common Stock, $0.001 par value, outstanding on October 31, 2002, was 15,000,003 shares, held by approximately 40 shareholders. On November 1, 2002 Willow Holdings Limited returned 9,931,261 shares of common stock to the Company for cancellation, which upon cancellation the Company will have 5,068,742 shares outstanding.

Transitional Small Business Disclosure Format (check one):

Yes __X__ No ____

NATUROL HOLDINGS LTD.
(Formerly Coronado Explorations Ltd.)
SEPTEMBER 30, 2002
INDEX

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

NATUROL HOLDINGS LTD.
(Formerly Coronado Explorations Ltd.)
(A Development Stage Company)
CONDENSED BALANCE SHEETS

	September 30, 2002 (Unaudited)	January 31, 2002
Assets		
Current Assets:		
Cash	$ 629	$ 4,831
Total current assets	629	4,831
Investment in and advances to Naturol Canada Limited	- -	31
	$ 629	$ 4,862
Liabilities and Shareholders' Deficit:		
Current liabilities:		
Accounts payable	$ 74,294	$ 62,038
Note payable	112,657	26,565
Due to Naturol Canada Limited	- -	31
Total current liabilities	186,951	88,634
Investment in and advances to Naturol Canada Limited	76,602	- -
Shareholders' Deficit:		
Common stock 200,000,000 shares authorized par value $.001, 15,000,003 shares issued and outstanding at September 30, 2002 and January 31, 2002	15,000	15,000
Paid-in-capital	62,250	90,650
Subscriptions receivable	- -	(28,400)
Deficit accumulated during the developmental stage	(340,174)	(161,022)
Total shareholders' deficit	(262,924)	(83,772)
Total liabilities and shareholders' deficit	$ 629	$ 4,862

See notes to condensed financial statements

NATUROL HOLDINGS LTD.
(Formerly Coronado Explorations Ltd.)
(A Development Stage Company)
CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)

	Two Months Ended September 30, 2002	Two Months Ended September 30, 2001	Eight Months Ended September 30, 2002	Eight Months Ended September 30, 2001	From Inception June 18, 2001 to September 30, 2002
Revenues	$ - -	$ - -	$ - -	$ - -	$ - -
Expenses:					
Professional fees	30,931	(20,000)	(67,219)	(20,000)	(164,817)
License fees	- -	- -	- -	- -	(50,000)
Interest expense	(2,748)	- -	(6,092)	- -	(6,157)
Equity in net loss of affiliate	(20,031)	- -	(80,477)	- -	(80,477)
Office expense	(851)	- -	(9,969)	- -	(23,328)
Travel & entertainment	5,062	- -	(15,395)	- -	(15,395)
Total Expenses	12,363	(20,000)	(179,152)	(20,000)	(340,174)
Net Income (loss)	$ 12,363	$ (20,000)	$ (179,152)	$ (20,000)	$ (340,174)
Net Income (loss) per share basic and diluted	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.00)	$ (0.02)
Weighted average shares outstanding	15,000,003	9,723,000	15,000,003	9,723,000	14,853,956

See notes to condensed financial statements

NATUROL HOLDINGS LTD.
(Formerly Coronado Explorations Ltd.)
(A Development Stage Company)
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)

	Eight Months Ended September 30, 2002	Eight Months Ended September 30, 2001	From Inception June 18, 2001 to September 30, 2002
Cash flows from operating activities:			
Net loss	$ (179,152)	$ (20,000)	$ (340,174)
Changes in operating assets and liabilities:			
Accounts payable	12,256	- -	74,294
Cash used in operating activities	(166,896)	(20,000)	(265,880)
Cash flows from financing activities:			
Increase in note payable	86,093	- -	86,158
Proceeds from the sale of common stock	- -	73,750	103,750
	86,093	73,750	189,907
Cash flows from investing activities:			
Investment in and advances to Naturol Canada Limited	76,602	- -	76,602
Increase in cash	(4,202)	53,750	629
Cash beginning of period	4,831	- -	- -
Cash end of period	$ 629	$ 53,750	$ 629
Supplemental disclosure of cash flow information:			
Cash paid for interest	$ - -	$ - -	$ - -
Cash paid for income taxes	- -	- -	- -
Non-cash financing activities:			
Stock issued for subscription receivable	$ - -	$ - -	$ 28,400
Stock issued and note assumed in reverse merger	- -	- -	52,765
Investment in affiliated company	- -	- -	31

See notes to condensed financial statements

NATUROL HOLDINGS LTD.
(Formerly Coronado Explorations Ltd.)
(A Development Stage Company)
NOTES TO CONDENSED FINANCIAL STATEMENTS

Note 1 - Basis of Presentation

The unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB and reflect all adjustments which, in the opinion of management, are necessary for a fair presentation. All such adjustments are of a normal recurring nature. The results of operations for the interim period are not necessarily indicative of the results to be expected for a full year. Certain amounts in the prior year statements have been reclassified to conform to the current year presentations. The statements should be read in conjunction with the financial statements and footnotes thereto included in the Company's Form 10-KSB for the year ended January 31, 2002.

Note 2 - Commitments and Contingencies

Going Concern

The accompanying condensed financial statements have been prepared assuming that the Company will continue as a going concern. The ability of the Company to continue as a going concern is dependent upon management to attain profitable operations based on the development of products that can be sold. Management intends to use borrowings and security sales to mitigate the affects of its cash position, however no assurance can be given that debt or equity financing, if and when required, will be available. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Note 3 - Note Payable

The Company in the period ended September 30, 2002 and for the eight month period ended September 30, 2002 has borrowed $0 and $75,000 respectively from a shareholder. The demand note has an interest rate of 10%. Total borrowed including unpaid interest at September 30, 2002 was $112,657.

Note 4 - Marketing Agreement

The Company entered into a media and public relations consulting agreement for a term of one year requiring a $6,000 per month consulting fee commencing on April 1, 2002. The agreement was terminated in May 2002.

Note 5 - Investment in Naturol Canada Limited

An investment in Naturol Canada Limited is accounted for under the equity method as the Company owns 49% of the outstanding stock. During the period ended September 30, 2002 the Company has recorded a $20,031 loss on the investment which represented the Company's percentage ownership of the total loss. The year to date loss is $80,477.

Note 6- Related Party transactions

Naturol Canada was charged $19,960 in the current fiscal year for consulting services by an Officer of the Company.

Note 7-Name Change and Year End Change

The Company changed its name to Naturol Holdings Ltd on July 23, 2002. The Company also changed its year-end from January 31 to December 31. The operating results for the period ended September 30 is for the period of August 1 through September 30. For the year to date activity the operating results are for the period of February 1 through September 30.

Note 8-Agreement With MGA Holdings Limited

The Company in September 2002 amended its license agreement with MGA Holdings Limited (formerly Naturol UK Limited). The agreement gave the Company a perpetual, non-transferable, non-exclusive license for products developed or marketed using MGA's process in North America. The Company will make payments to MGA tied solely to revenues earned from the sale of products directly related to MGA's process. The Company will no longer be liable for a license fee of $310,000 that was previously due to MGA. An affiliate of MGA, and majority shareholder of the Company, will return to the Company 9,931,261 common stock shares held by Willow Holdings. MGA will not be reimbursed for travel expenses totaling $5,285 which was recorded as a payable on the Company's books and MGA will assume $76,879 that is due to an attorney firm of a Director of the Company for professional services that was recorded as an account payable on the Company's books. In the period ended September 30, 2002 the reversal of $76,879 in professional fees resulted in the total for the period to be a negative expense of $30,931. Travel expense was reduced by $5,285 resulting from the reversal of the payable to MGA.

Note 9-Subsequent Events

On November 1, 2002 Willow Holdings returned the 9,931,261 shares of Company stock and the shares were cancelled**.**

Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with the Company's financial statements and the notes thereto contained elsewhere in this filing.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

With the exception of historical matters, the matters discussed herein are forward-looking statements that involve risks and uncertainties. Forward-looking statements include, but are not limited to, statements concerning anticipated revenues and net income, projections concerning operations and available cash flow. The Company's actual results could differ materially from the results discussed in such forward-looking statements.

The Company wishes to caution investors that any forward-looking statements made by or on behalf of the Company are subject to uncertainties and other factors that could cause actual results to differ materially from such statements. These uncertainties and other factors include, but are not limited to the Risk Factors listed below (many of which have been discussed in prior SEC filings by the Company). Though the Company has attempted to list comprehensively these important factors, the Company wishes to caution investors that other factors could in the future prove to be important in affecting the Company's results of operations. New factors emerge from time to time and it is not possible for management to predict all of such factors, nor can it assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Readers are further cautioned not to place undue reliance on such forward-looking statements as they speak only of the Company's views as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Background Overview

On January 17, 2002, Coronado Explorations Ltd. (now Naturol Holdings Ltd.) completed a reverse triangular merger between Coronado Subsidiary Corp. ("CSC"), a Nevada corporation and a wholly owned subsidiary of Coronado, and Naturol Inc., a Nevada corporation ("Naturol"), whereby Naturol merged with CSC wherein CSC ceased to exist and Naturol became a wholly owned subsidiary of the Company. Prior to the Merger, the Company was engaged in the exploration of mineral properties and subsequently became a shell corporation. All business of the Company is now conducted through its wholly owned subsidiary, Naturol. Naturol owns a non-exclusive North American License for extraction technologies employed in the flavors, fragrances and pharmaceutical industries.

The Company is a development stage company, has no revenues to date and has raised capital for initial development through the issuance of its securities.

The financial statements presented are of Naturol for the two months ending September 30, 2002. Naturol's fiscal year end is December 31. The financial statements included in this filing are for the Company's transition period, containing unaudited interim financial statements for the two-month period from August 1, 2002 to September 30, 2002.

As a result of the merger and the insignificance of Coronado's financial information as a shell corporation, the presentation of financial information is of Naturol from inception.

Recent Developments

During August of 2002, Naturol received correspondence from MGA Holdings Limited, which indicated MGA's intention to default Naturol for its failure to meet its obligations under the terms of the License Agreement, and take a course of action including termination of the License Agreement. On or about August 23, 2002, MGA informed Naturol that MGA would not take a default action against Naturol for its failure to meet the provisions of the terms of the License Agreement, however no continuing term for the waiver of default was agreed upon. On September 20, 2002, the Company entered into a new, revised non-exclusive License Agreement with MGA.

The material differences between the original exclusive License Agreement dated August 17th, 2001 and the Non-exclusive License Agreement dated September 18th, 2002 are as follows:

- The revised Non-exclusive License Agreement provides for MGA, the Licensor, to allow for the granting of other licenses within the licensed territory, ie Canada, United States, and Mexico.
- The revised Non-exclusive License Agreement has no minimum annual royalty payment.

Plan of Operation

Since our operations have been solely based on Naturol's business since Naturol became a wholly owned subsidiary of the Company on January 17, 2002, our plan of operation has assumed the plan of operation of Naturol. Naturol's business is to eventually provide a service of extraction employing the Naturol Extraction Technology. However, due to the recent events surrounding the license agreement with MGA and the subsequent conversion of the license to a non-exclusive, the Company anticipates the need to redevelop and further analyze its plan of operation. We are actively pursuing the search for acquisitions or merger of companies compatible with our technology. However, we are also reviewing other possibilities which do not include our technology. In one instance we have executed a non-binding letter of intent to possibly pursue a merger with a private company.

We plan on satisfying our cash obligations over the next twelve months through additional equity and/or third party financing. We do not anticipate generating revenues sufficient enough to satisfy our working capital requirements within the next twelve months.

Commercialization of Naturol Extraction Technology is a function, to a large extent, of the benefits of the efforts of the commercial research and development program launched in March 2002 at the Prince Edward Island Food Technology Center. Under the terms of the revised non-exclusive License Agreement executed between Naturol and MGA Holdings, this program will now be under the operational control of MGA Holdings. Notwithstanding, MGA Holdings has agreed to grant Naturol complete access to all technological developments resulting from this program. Management is unable at this time to predict how this will impact the Company's ability to continue to attempt to commercialize the Naturol Extraction Technology.

As a result of our agreement between Naturol (Canada) Limited and the National Research Council Canada, a commercial research and development program is being conducted at the Prince

Edward Island Food Technology Center based in Charlottetown, Prince Edward Island, Canada at a total cost of approximately $326,600, of which Naturol (Canada) Limited is obligated to pay $109,300. This obligation has been assumed by MGA as part of the agreements reached with them in September 2002. The Prince Edward Island Food Technology Center is a provincially funded facility providing a range of services to the agri-food and seafood processing industries. Its resources include project management, laboratory analysis, technical support, applications development and biomass extraction technology.

Risks that could cause actual performance to differ from expected performance are detailed in the remainder of this section, and under the section titled "Factors That May Affect the Company's Future Operating Results."

Liquidity and Capital Resources

A critical component of our operating plan impacting our continued existence is the ability to obtain additional capital through additional equity and/or debt financing. We do not anticipate enough positive internal operating cash flow until such time as we can generate substantial revenues from fees earned as a result of our Naturol Extraction Technology, which may take the next few years to fully realize. In the event we cannot obtain the necessary capital to pursue our strategic plan, we may have to cease or significantly curtail our operations. This would materially impact our ability to continue operations.

Our near term cash requirements are anticipated to be offset through the receipt of funds from private placement offerings and loans obtained through private sources. Since inception, we have financed cash flow requirements through debt financing and issuance of common stock for cash and services. As we expand operational activities, we may continue to experience net negative cash flows from operations, pending receipt of servicing or licensing fees, and will be required to obtain additional financing to fund operations through common stock offerings and bank borrowings to the extent necessary to provide working capital.

Over the next twelve months we believe that existing capital and anticipated funds from operations will not be sufficient to sustain operations and planned expansion. Consequently, we will be required to seek additional capital in the future to fund growth and expansion through additional equity or debt financing or credit facilities. No assurance can be made that such financing would be available, and if available it may take either the form of debt or equity. In either case, the financing could have a negative impact on our financial condition and our Stockholders.

We anticipate incurring operating losses over the next twelve months. Our lack of operating history makes predictions of future operating results difficult to ascertain. Our prospects must be considered in light of the risks, expenses and difficulties frequently encountered by companies in their early stage of development, particularly companies in new and rapidly evolving markets such as technology related companies. Such risks include, but are not limited to, an evolving and unpredictable business model and the management of growth. To address these risks we must, among other things, obtain a customer base, implement and successfully execute our business and marketing strategy, continue to develop and upgrade technology and products, provide superior extraction results, file patent applications to cover new processing technology and new compositions discovered during our research and development efforts, conduct tests in support of, and file with FDA for use of Naturol solvents as food contacting materials, respond to competitive developments,, and attract, retain and motivate qualified personnel. There can be no assurance that we will be successful in addressing such risks, and the failure to do so can have a material adverse effect on our business prospects, financial condition and results of operations.

As of September 30, 2002, the Company had assets of $629, and $186,951 of current liabilities. The current liabilities include accounts payable of $74,294 and notes payable of $112,657.

Attestation of President and Chief Financial Officer as to our internal controls

Our President and interim Chief Financial Officer has evaluated the effectiveness of our internal controls and has found that based on these evaluations and the current status of the Company's operations that our internal controls are adequate at this time. Further, there have been no significant changes in our internal controls or in other factors that could significantly affect internal controls subsequent to the date of its evaluations.

FACTORS THAT MAY AFFECT THE COMPANY'S FUTURE OPERATING RESULTS

Going Concern; Need For Additional Capital

Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have suffered losses from operations during our operating history and our ability to continue as a going concern is dependent upon obtaining future profitable operations. Our business is capital intensive. Although management believes that the proceeds from the sale of its securities, together with funds from operations, will be sufficient to cover its anticipated cash requirements, the Company may be required to seek additional capital to fund future growth and expansion. No assurance can be given that such financing will be available or, if available, that it will be on commercially favorable terms. Moreover, favorable financing may be dilutive to investors.

Limited History of Business Operations; Accumulated Losses

We have only a limited operating history and our business model has not yet been tested in the market place. Our prospects must be considered in light of the risks, expenses and difficulties frequently encountered in establishing a business in the medical food or nutraceutical industry, which are characterized by a large number of market entrants, intense competition and a high failure rate. To date, we have been engaged primarily in start-up and business development activities and have generated little revenue from product sales. To achieve profitable operations, we, alone or with others, must successfully introduce and market our existing product, and develop, introduce and market new products. No assurance can be given that our product development efforts will be successfully completed, or that any product, if introduced, will be successfully marketed or will achieve customer acceptance. Future operating results will depend on many factors, including the demand for our products, the level of competition and our ability to cause the manufacture of our products in a production environment while maintaining quality and controlling costs.

Although we are not a pharmaceutical development company, any research and development activities, by its very nature, precludes definitive statements as to the time required and costs involved in reaching certain objectives. Although our research and development will be relatively limited, actual research and development costs may exceed budgeted amounts and estimated time frames may require extension. Cost overruns due to unanticipated clinical or regulatory delays or demands, unexpected adverse side effects, insufficient therapeutic efficacy or competitive or technological developments would prevent or substantially deter development efforts and ultimately could have a material adverse effect on us. Our existing product candidates, and any potential additional products that may be developed, may, in certain instances, require significant additional research and development, possible regulatory approval and commitments of resources prior to commercialization. There can be no assurance that any such potential products will be successfully developed or capable of being produced in commercial quantities at acceptable costs, or that any product will prove to be safe and effective in clinical trials or otherwise, or meet applicable regulatory standards.

There is a limited current public market for our common stock.

Although our common stock is listed on the Over-the-Counter Bulletin Board, there is a limited volume of sales, thus providing a limited liquidity into the market for our shares. As a result of the foregoing, shareholders may be unable to liquidate their shares for any reason.

Risks of Acquisition or Merger

As part of our ongoing operations we are seeking acquisition and merger candidates to diversify our holdings. We intend on acquiring businesses that we believe are complimentary to our operations, however, there is a substantial likelihood that due to uniqueness of our technology and current operations, any potential acquisition targets will be in drastically different business industries than we are. While we believe we would effectively integrate such businesses with our own, we may be unable to successfully do so without losing key employees or business relationships. In addition, we may be unable to smoothly integrate the acquired companies' marketing, production, development, distribution and management systems, resulting in our inability to realize hoped for cost savings and/or sales growth. Our gross margins could be adversely affected by any problems arising during or from such process or the inability to effectively integrate any future acquisitions.

PART II--OTHER INFORMATION

Item 1. Legal Proceedings.

None

Item 2. Changes in Securities.

Subsequent Event:

On November 1, 2002, Willow Holdings Limited returned 9,931,261 shares of common stock to the Company for cancellation. See Item 5 for further discussion regarding this transaction.

Item 3. Defaults by the Company upon its Senior Securities.

None.

Item 4. Submission of Matter to a Vote of Security Holders.

None

Item 5. Other Information.

MGA Agreement

During August of 2002, Naturol received correspondence from MGA Holdings Limited, which indicated MGA's intention to default Naturol on the License Agreement, and take a course of action including termination of the License Agreement for failure by Naturol to meet its obligations under the terms of the License Agreement. On September 20, 2002, following various negotiations between the Parties, the Company entered into a Letter Agreement among MGA, Willow Holdings Limited (our then majority stockholder) and Naturol Canada. A copy of the Letter Agreement is attached hereto as Exhibit 10.1.

Material terms of the Letter Agreement were as follows:

- MGA waived all payment obligations by Naturol under the License Agreement up to September 18, 2002.

- MGA and Naturol executed a new non-exclusive license agreement, a copy of which is attached hereto as Exhibit 10.2. The Amended Non-exclusive License Agreement supercedes all terms and conditions of the original License Agreement.

- In the event that Naturol is able to secure sufficient funding to fully implement its business plan, Naturol may request, and MGA, the Licensor, "shall convert the Non-exclusive License to an exclusive license with mutually agreeable payment terms, said payment terms being based solely on income generated by Licensee," (Naturol). The agreement specifies this will occur, "as long as no additional licenses have been granted in the Territory."

- As a result of Naturol giving up its exclusive License Agreement in exchange for a Non-exclusive License Agreement, Willow agreed, for no other consideration, to return to Naturol 9,931,321 shares of common stock of Naturol issued to Willow in exchange for the original exclusive License Agreement. On November 1, 2002 the shares were returned to the Company and were subsequently cancelled.

- MGA assumed operational control of Naturol Canada Limited, but will continue to grant Naturol complete access to all technological developments resulting from the commercial research and development program conducted on behalf of Naturol Canada at the Prince Edward Island Food Technology Center. Naturol Canada is 49% owned by Naturol and 51% owned by Isaac Moss, an officer and director of Naturol, in trust for Naturol. Naturol Canada Limited has no assets and is purely a research and development company.

- MGA assumed and indemnified Naturol of all outstanding financial obligations incurred by Naturol or Naturol Canada Limited in reference to the activities of Naturol Canada Limited, including but not limited to the obligations to the National Research Council of Canada Industrial Research Assistance Program Contribution to Firms Agreement. Additionally, MGA will continue to pay all future financial obligations of Naturol Canada Limited relating to obligations of Naturol Canada

Limited to National Research Council of Canada Industrial Research Assistance Program Contribution to Firms Agreement.

- MGA assumed all financial obligations relating to patent and licensing issues, including past obligations by Naturol to patent counsel in an aggregate amount of $76,879.

The material differences between the original exclusive License Agreement dated August 17th, 2001 and the Non-exclusive License Agreement dated September 18th, 2002 are as follows:

- The revised Non-exclusive License Agreement provides for MGA, the Licensor, to allow for the granting of other licenses within the licensed territory, ie Canada, United States, and Mexico.
- The revised Non-exclusive License Agreement has no minimum annual payment.

In addition, concurrent with the actions taken above, Paul McClory, then President, CEO and a director of the Company, immediately resigned as an officer and director of the Company.

Change of Year End/Transition Period

On July 23, 2002, the Registrant changed its fiscal year end from 1/31 to 12/31. This filing contains interim unaudited financial statements for the two-month period from August 1, 2002 to September 30, 2002.

Item 6. Exhibits and Reports on Form 8-K.

10.1- Letter Agreement
10.2- Non-Exclusive License Agreement

SIGNATURES

Pursuant t the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NATUROL HOLDINGS LTD.
(Registrant)

By: Isaac Moss

Isaac Moss,
President/Secretary/Treasurer/Director

CERTIFICATION PURSUANT TO
18 USC, SECTION 1350, AS ADOPTED PURSUANT TO
SECTIONS 302 AND 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Naturol Holdings Ltd. (the "Company") on Form 10-QSB for the period ending September 30, 2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Isaac Moss, President and Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, that:

(1) I have reviewed the report;

(2) To the best of my knowledge, the Report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading:

(3) To the best of my knowledge, the financial statements, and other financial information included in the Report, fairly present in all material respects the financial condition and results of operations of the Company as of, and for, the periods presented in the Report;

(4) I:
(a) am responsible for establishing internal controls;
(b) have designed such internal controls to ensure that material information relating to the Company and its consolidated subsidiaries is made known to us by others within the Company, particularly during the period ended September 30, 2002;
(c) have evaluated the effectiveness of the Company's internal controls as of a date within 90 days prior to the Report; and
(d) have presented in the Report our conclusions about the effectiveness of our internal controls based on our evaluation of that date;

(5) I have disclosed to the Company's auditors and the board of directors:
(a) all significant deficiencies in the design or operation of internal controls which could adversely affect the Company's ability to record, process, summarize, and report financial data and have identified for the Company's auditors any material weaknesses in internal controls; and
(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal controls;

(6) I have indicated in the Report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of my evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses; and

(7) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934.

Date: November 7, 2002

Isaac Moss, President/Interim Chief Financial Officer